Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

Methods of Nuclear Reprogramming

Methods of Nuclear Reprogramming

Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tunable gene expression in zebrafish using RiboSCALE.

bioRxiv : the preprint server for biology·2026

Same author

Publisher Correction: Unlocking chemical diversity in aptamers with DNA orthogonal barcodes.

Nature chemistry·2026

Same author

Unlocking chemical diversity in aptamers with DNA orthogonal barcodes.

Nature chemistry·2026

Same author

From Selection to Use: Aptamers as Targeting Reagents in Hematology.

Biomedicines·2026

Same author

One size does not fit all: A comparative framework for optimizing ribonucleic acid transfection across acute myeloid leukemia cell lines.

Biology methods & protocols·2026

Same author

Albumin-binding dendrimer-conjugated siRNA enables safe and effective gene silencing throughout the central nervous system.

bioRxiv : the preprint server for biology·2025

Search research articles

Related Experiment Video

Updated: Oct 9, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Enhancing CAR-T Cell Therapy with Functional Nucleic Acids.

Bruktawit Maru¹, Lea Nadeau¹, Maureen McKeague^1,2

¹Pharmacology and Therapeutics, Faculty of Medicine, McGill University, 3655 Promenade Sir William Osler, Montreal, QC H3G 1Y6, Canada.

ACS Pharmacology & Translational Science

|December 20, 2021

Summary

This summary is machine-generated.

Functional nucleic acids like aptamers and ribozymes offer novel solutions to enhance chimeric antigen receptor (CAR) T cell therapy development. These tools show promise in overcoming challenges and improving clinical applications of this immunotherapy.

More Related Videos

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Oct 9, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Immunotherapy
Molecular Biology
Biotechnology

Background:

Chimeric antigen receptor (CAR) T cell therapy is an emerging immunotherapy with FDA approvals for hematologic malignancies.
Widespread adoption of CAR-T therapy is limited by several existing challenges.
Functional nucleic acids (FNAs) represent a class of molecules with diverse biological applications.

Purpose of the Study:

To review the application of functional nucleic acids (FNAs), specifically aptamers and ribozymes, in CAR-T cell therapy.
To examine the potential of FNAs to improve various stages of CAR-T cell therapy development.
To discuss the clinical feasibility and future opportunities for FNA integration in immunotherapy.

Main Methods:

Literature review of key studies on the use of aptamers and ribozymes in cell-based therapies.
Critical analysis of the benefits and challenges associated with FNA incorporation.
Discussion of potential chemical contributions to FNA-based CAR-T cell therapy innovation.

Main Results:

Functional nucleic acids demonstrate significant potential to enhance CAR-T cell therapy.
Aptamers and ribozymes can be applied to improve multiple steps in CAR-T cell development and function.
Studies highlight the benefits of FNAs in overcoming current limitations of CAR-T therapy.

Conclusions:

Functional nucleic acids offer promising tools to advance CAR-T cell therapy.
Strategic incorporation of FNAs can address key challenges, paving the way for broader clinical application.
Chemists play a crucial role in developing innovative FNA-based solutions for next-generation immunotherapies.